Financials data is unavailable for this security.

Inc stmt in GBPIncome statement in GBPView more

Year on year GlaxoSmithKline PLC grew net income 205.59% from 2.76bn to 8.42bn primarily through revenue growth (23.01bn to 23.92bn). For while the costs associated with cost of goods, selling, general and administrative and debt all increased as a percentage of sales, the 3.99% growth in revenues contributed enough to still see net income improve.
Gross margin67.01%
Net profit margin1.19%
Operating margin6.58%
Return on assets0.56%
Return on equity10.81%
Return on investment0.87%
More ▼

Cash flow in GBPView more

In 2015, GlaxoSmithKline PLC increased its cash reserves by 36.20%, or 1.46bn. Cash Flow from Investing totalled 6.04bn, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company generated 2.57bn in cash from operations while cash used for financing totalled 7.10bn.
Cash flow per share0.4154
Price/Cash flow per share39.28
Book value per share0.0283
Tangible book value per share-4.96
More ▼

Balance sheet in GBPView more

GlaxoSmithKline PLC has a Debt to Total Capital ratio of 82.89%, a lower figure than the previous year's 278.18%.
Current ratio0.971
Quick ratio0.6748
Total debt/total equity140.30
Total debt/total capital0.8289
More ▼

Growth rates in GBP

Year on year, growth in dividends per share remained flat while earnings per share excluding extraordinary items increased 204.15%. Additionally when measured on a five year annualized basis, dividend per share growth is in-line with the industry average relative to its peers, while earnings per share growth is the highest in its industry.
Div yield(5 year avg)0.05%
Div growth rate (5 year)4.24%
Payout ratio (TTM)1,611.96%
EPS growth(5 years)40.15
EPS (TTM) vs
TTM 1 year ago
More ▼
© Thomson Reuters Click for restrictions
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.